Borchmann P, Ferdinandus J, Schneider G, Moccia A, et al. Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial. Lancet 2024 Jul 3:S0140-6736(24)01315-1. doi: 10.1016/S0140-6736(24)01315.
PMID: 38971175